Related Experiment Video

Updated: May 22, 2025

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors
10:33

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors

Published on: October 26, 2015

11.3K

Binding Mechanism of Inhibitors to CDK6 Deciphered by Multiple Independent Molecular Dynamics Simulations and Free

Lifei Wang1, Yan Wang1, Lulu Zhang1

  • 1School of Science, Shandong Jiaotong University, Jinan 250357, China.

Molecules (Basel, Switzerland)
|March 13, 2025
PubMed

Insights

This study reveals how three inhibitors bind to cyclin-dependent kinase 6 (CDK6) using molecular dynamics. Hydrophobic interactions and specific residues are key for potent CDK6 inhibitor development.

Area of Science:

  • Molecular Biology
  • Biochemistry
  • Computational Chemistry

Background:

  • Cyclin-dependent kinase 6 (CDK6) is a validated drug target in oncology.
  • Understanding CDK6 inhibitor binding mechanisms is crucial for cancer therapy development.

Purpose of the Study:

  • To elucidate the binding mechanisms of three inhibitors (LQQ, 6ZV, 0RS) to CDK6.
  • To identify critical interaction sites and driving forces for inhibitor-CDK6 binding.

Main Methods:

  • Multiple independent molecular dynamics (MD) simulations with four replicates.
  • Binding free energy calculations using the Molecular Mechanics Generalized Born Surface Area (MM-GBSA) approach.
  • Residue-based free energy decomposition analysis.

Main Results:

  • Inhibitor binding induces conformational changes and alters the internal dynamics of CDK6.
  • Hydrophobic interactions are essential for the binding of LQQ, 6ZV, and 0RS to CDK6.
  • Specific residues (I19, K29, M54, P55, F98, H100, L152) significantly contribute to inhibitor binding.

Conclusions:

  • The study provides insights into the molecular basis of CDK6 inhibitor binding.
  • Identified key residues and interactions can guide the design of novel and potent CDK6 inhibitors.
  • This research offers theoretical support for developing targeted therapies against CDK family proteins in cancer.
Keywords:
GB modelsMM-GBSAcyclin-dependent kinase 6multiple independent molecular dynamicsprincipal component analysis

More Related Videos

Identification of Cyclin-dependent Kinase 1 Specific Phosphorylation Sites by an In Vitro Kinase Assay12:26

Identification of Cyclin-dependent Kinase 1 Specific Phosphorylation Sites by an In Vitro Kinase Assay

Published on: May 3, 2018

18.5K
Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors10:29

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors

Published on: May 9, 2025

161

Related Concept Videos

Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.6K
Positive Regulator Molecules02:39

Positive Regulator Molecules

Mitotic cell division results in daughter cells that exactly resemble the parent cell. However, errors in the DNA replication or distribution of genetic material may lead to genetic mutations that may be passed down to every new cell formed from the resulting abnormal cell. Propagation of such mutant cells is restricted through checkpoint mechanisms present at different stages of the cell cycle. These checkpoints involve regulator molecules that either promote or demote cell cycle events.
5.3K
M-Cdk Drives Transition Into Mitosis02:15

M-Cdk Drives Transition Into Mitosis

Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
5.5K
The Equilibrium Binding Constant and Binding Strength02:18

The Equilibrium Binding Constant and Binding Strength

The equilibrium binding constant (Kb) quantifies the strength of a protein-ligand interaction. Kb can be calculated as follows when the reaction is at equilibrium:
12.7K
Enzymes02:34

Enzymes

Inside living organisms, enzymes act as catalysts for many biochemical reactions involved in cellular metabolism. The role of enzymes is to reduce the activation energies of biochemical reactions by forming complexes with its substrates. The lowering of activation energies favor an increase in the rates of biochemical reactions.
Enzyme deficiencies can often translate into life-threatening diseases. For example, a genetic abnormality resulting in the deficiency of the enzyme G6PD...
80.3K
Enzyme Inhibition01:30

Enzyme Inhibition

Inhibitors are molecules that reduce enzyme activity by binding to the enzyme. In a normally functioning cell, enzymes are regulated by a variety of inhibitors. Drugs and other toxins can also inhibit enzymes. Some inhibitors bind to the enzyme’s active site, while others inhibit enzymatic activity by binding to other sites on the protein structure.
77.7K